Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen

Sohag University

Status and phase: Active, not recruiting; Phase 2

Conditions: Colorectal Cancer

Treatments: Drug: Arm A:Dose_dense Capecitabine in Colorectal cancer; Drug: Arm B : standard dose Capecitabine

Study type: Interventional

Funder types: Other

Identifiers

NCT07215936

Soh_med_25_9___4MD

Details and patient eligibility

About

Dose_dense Capecitabine Schedule in colorectal cancers

Full description

Dose_dense Capecitabine schedule[7 days on_7days off] in colorectal cancer in comparison with standerd regimen

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who diagnosed colorectal cancer Performance status ranging from 0 to 2 Both sexs

Exclusion criteria

• pateints with other malignancy Pateints who have other comorbid diseas

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Arm A :will receive capecitabine dose dense 1750 mg /m2 7days on treatment and 7 days off

Active Comparator group

Treatment:

Drug: Arm A:Dose_dense Capecitabine in Colorectal cancer

Arm B will receive capecitabine standard dose 1000mg/m2 2weeks on and 1 week off

Active Comparator group

Treatment:

Drug: Arm B : standard dose Capecitabine